GQ1005

Phase 3Small molecule

GGeneQuantum Healthcare (Suzhou) Co., Ltd.

GQ1005 is one of 14 small molecule programs targeting HER2-positive Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2-Positive Breast CancerRecruiting

HER2-Positive Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

14 competitors in HER2-Positive Breast Cancer

#DrugCompanyPhaseTrials

Perjeta

Roche

Phase 3

3 2

Herceptin

OOrganon and Co

Phase 3

4 3

Taxotere

AAvyxa

Phase 3

2 4

Paraplatin

AAvyxa

Phase 3

2 5

Taxol

Teva

Phase 2

2 6

Keytruda

Merck & Co.

Phase 2

1 7

Zaniducla

Jazz Pharmaceuticals

Phase 2

1 8

KN026

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

1 9

T-DM1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

HER2-Positive Breast Cancer

NCT07673029

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Unknown status·GGeneQuantum Healthcare (Suzhou) Co., Ltd.·Phase 1·NCT06154343·150 enrolled

HER2-positive Breast Cancer1 trial

A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane

Recruiting·GGeneQuantum Healthcare (Suzhou) Co., Ltd.·Phase 3·NCT07673029·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GQ1005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GQ1005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GQ1005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GeneQuantum Healthcare (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGeneQuantum Healthcare (Suzhou) Co., Ltd.

GQ1005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

HER2-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News